-

TWKS Investigation Reminder - Robbins LLP Reminds Stockholders It Is Investigating the Acquisition of Thoughtworks Holding, Inc. (TWKS) by Apax Partners LLP

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the acquisition of Thoughtworks Holding, Inc. (NASDAQ: TWKS) by an affiliate of funds advised by Apax Partners LLP, which will purchase all of the outstanding shares of Thoughtworks common stock that they do not already own.

If you own shares of Thoughtworks, submit a form, email attorney Aaron Dumas, Jr. or give us a call at (800) 350-6003.

Is the Proposed Acquisition Best for Thoughtworks Holding, Inc. (TWKS) and its Shareholders?

On August 5, 2024, Thoughtworks announced a deal to be acquired by an affiliate of funds advised by Apax Partners LLP in a take private transaction. According to the news release, Thoughtworks' board of directors approved the merger agreement for $4.40 per share in cash. The deal is valued at approximately $1.75 billion and is expected to close in the fourth quarter of 2024. Robbins LLP is concerned that Thoughtworks' board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of Thoughtworks Holding, Inc. (TWKS) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion in value for shareholders. To be notified if a class action against Thoughtworks Holding, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:TWKS

Release Summary
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Thoughtworks Holding, Inc. (TWKS) by Apax Partners LLP
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Informs Stockholders it is Investigating Potential Securities Claims Involving Wealthfront Corporation

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Wealthfront Corporation (NASDAQ: WLTH) to determine whether certain Wealthfront officers and directors violated securities laws and breached fiduciary duties to shareholders.Why Are We Investigating Wealthfront?Wealthfront completed its initial public offering in December 2025, offering 34,615,384 shares of common stock at $14.00 per share, including shares sold by the Company and selling stockholders. The Compa...

Robbins LLP Informs Stockholders It Is Investigating Potential Securities Claims Involving Hyliion Holdings Corp.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Hyliion Holdings Corp. (AMEX: HYLN) to determine whether certain Hyliion Holdings officers and directors violated securities laws and breached fiduciary duties to shareholders. Hyliion is a power generator company whose primary product is the KARNQ Power Module.Why Are We Investigating Hyliion Holdings?Hyliion stock dropped 16% on Tuesday, June 23, 2026, following the release of a short-seller report from Pelica...

Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom